1. Home
  2. Programs
  3. Advances in Women's Health

Evaluating the Efficacy of Zuranolone for Postpartum Depression

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
  • Overview

    Zuranolone is the first oral drug approved by the FDA for the treatment of postpartum depression. Based on a recent systemic review and meta-analysis, it could provide rapid relief from symptoms within two weeks. Here to discuss the study’s findings and the potential impacts for patients suffering from postpartum depression is Dr. Elijah Salzer. Dr. Salzer is a Clinical Professor at the Pace University-Lenox Hill Hospital PA Program and staff physician assistant in gynecology at Eastchester Medical Associates.

Recommended
Details
Presenters
  • Overview

    Zuranolone is the first oral drug approved by the FDA for the treatment of postpartum depression. Based on a recent systemic review and meta-analysis, it could provide rapid relief from symptoms within two weeks. Here to discuss the study’s findings and the potential impacts for patients suffering from postpartum depression is Dr. Elijah Salzer. Dr. Salzer is a Clinical Professor at the Pace University-Lenox Hill Hospital PA Program and staff physician assistant in gynecology at Eastchester Medical Associates.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free